Sulfanilamide Crystalline Veterinary Grade API is the unsubstituted para-aminobenzenesulfonamide, CAS 63-74-1, with molecular formula C₆H₈N₂O₂S and molecular weight 172.20 g/mol. The crystalline material is a white to off-white powder intended for incorporation into tablets, injections, capsules, powders, granules, premix, and solutions for veterinary antimicrobial therapy. Manufacturer model designations separate unmicronized crystalline grade, micronized grade with D90 ≤50 µm, and injectable low-endotoxin grade; these material-class suffixes are logistical identifiers and do not replace compendial identity. Sulfanilamide contains a primary aromatic amine and a sulfonamide group, which together control diazotization titration, oxidative degradation behavior, and excipient compatibility.

The veterinary grade is controlled against compendial methods where applicable. Release specifications generally include assay on the anhydrous basis at 98.0–102.0%, loss on drying ≤0.5% after 105 °C for 2 h, residue on ignition ≤0.1%, and melting range 164–166 °C. Related substances are determined by stability-indicating HPLC. Residual solvent and microbial quality are additionally controlled according to USP <467> and USP <61>/USP <62>. Particle-size distribution and bulk density are reported in the manufacturer certificate of analysis because they alter downstream processing in every dosage form listed.

Table 1 lists representative release parameters for a crystalline veterinary grade. Specific acceptance criteria may vary by compendial edition, manufacturing site, and grade designation.

Why Does Crystal Habit and Particle Size Control Affect Every Downstream Veterinary Dosage Form?

Crystal habit and particle-size distribution produce opposing effects on formulation performance. Micronized sulfanilamide increases specific surface area and reduces dissolution lag in immediate-release tablets and oral suspensions, but it also increases cohesivity and static charge. Laser diffraction particle sizing according to ISO 13320:2020 is used to monitor D10, D50, and D90; a micronized veterinary grade typically has D90 ≤50 µm and D50 10–30 µm. When the D90 falls below 20 µm, the Carr compressibility index may exceed 25% and the Hausner ratio may exceed 1.34, which is a recognized powder-flow boundary for tablet compression. At this limit, direct compression is generally not robust, and dry granulation or wet granulation is required. Powder flow testing under USP <1174> is used to establish the blend and lubrication end point.

Jet milling and hammer milling introduce surface amorphization and modify bulk density. X-ray powder diffraction is used to confirm that the crystalline phase remains within the approved pattern, because surface amorphous content above site-specific thresholds can increase moisture sorption and chemical degradation. Drying of wet-cake material at temperatures above 70 °C can produce yellowing or melting point depression if residual solvent or impurities are present; therefore, controlled vacuum drying or forced-air drying with product temperature monitoring is standard. The unmicronized crystalline grade is preferred when granulation strength and densification are required, while the micronized grade is selected for low-dose content uniformity and rapid dissolution. Published data for the polymorphic transformation boundaries of this specific veterinary grade is limited; site-specific XRPD and moisture sorption profiles are required.

Tablet processing of sulfanilamide veterinary grade begins with particle-size selection and excipient compatibility screening. The API can be blended with microcrystalline cellulose, dicalcium phosphate, and sodium starch glycolate. Lactose-based diluents should be avoided in wet granulation because the primary aromatic amine can participate in Maillard-type degradation under heat and moisture. For low-dose tablets, a micronized grade with D90 ≤20 µm is preferred for blend uniformity, but flow function coefficients may be low; roller compaction with screen milling is then used to restore granule density. Blend uniformity is evaluated by unit-dose sampling and HPLC assay, with acceptance typically set at RSD ≤5.0%. Finished tablets should meet USP <905> uniformity of dosage units, USP <701> disintegration, and USP <711> dissolution where a monograph exists.

Over-blending with magnesium stearate beyond 5 min can delay dissolution through hydrophobic surface coverage; lubrication time and mixer speed are therefore controlled. Tablet hardness, friability per USP <1216>, and moisture content are monitored after compression. Capsule filling of sulfanilamide-containing blends requires control of powder flow and segregation; force-feeding equipment on rotary capsule fillers may densify the blend and alter dissolution. In-line bulk density and weight variation are monitored during filling. For capsules, dissolution testing is conducted with sink conditions that account for the sparing aqueous solubility of the unsubstituted sulfonamide, and media volumes may require pH 6.8 phosphate buffer or dilute hydrochloric acid to demonstrate complete release.

Production-scale failure modes in high-shear and low-shear blending include segregation of micronized API to the top of V-blenders and static adhesion to polyvinyl chloride transfer tubing. These failure modes are managed by grounding, humidity control, and order-of-addition sequencing. For roller compaction, insufficient roll pressure can generate weak ribbons that increase fines and compressibility index, while excessive pressure can reduce tablet dissolution by increasing granule hardness. Granule density is measured by tapped density and sieve retention, and compression settings are adjusted based on tablet hardness and disintegration time.

Injectable Solution Sterility and Particulate Control for Sulfanilamide Veterinary Grade

Injectable formulations require low-endotoxin sulfanilamide and strict control of solution clarity. Because sulfanilamide is sparingly soluble in water, liquid formulations frequently use co-solvents such as propylene glycol, glycerin, or dilute ethanol; pH adjustment may be used to form the more soluble sodium salt, but physiological pH and tissue compatibility limit the degree of alkalinization. Terminal steam sterilization at 121 °C for 15 min cannot be assumed to be stability-neutral for all formulations; aseptic filtration through a 0.22 µm membrane is often evaluated, and the final filled solution should comply with USP <71> sterility, USP <85> bacterial endotoxins, and USP <788> particulate matter.

Stability of injectable sulfanilamide solutions may be affected by light, oxygen, and trace transition metals. Nitrogen blanketing and chelating agents such as disodium edetate are evaluated when discoloration is observed during forced-degradation studies. Because sulfanilamide has a primary aromatic amine, oxidative coupling can generate colored by-products; filters, tubing, and container closures should be selected for low metal ion release. Published data for this specific injectable configuration is limited, so route-specific stability protocols are required before batch release.

Stability-indicating HPLC methods for sulfanilamide veterinary grade typically separate sulfanilamide from sulfanilic acid and related sulfonamide impurities. Diazotization titration is suitable for assay of the unsubstituted primary aromatic amine content, but it is not stability-indicating when degradants retain the primary amine. Forced-degradation studies include acid, base, oxidative, thermal, and photolytic conditions; mass balance is required in the range of 95–105% unless degradation products are identified. The crystalline API should show no significant change at 40 °C / 75% RH over 6 months in accelerated stability protocols, but site-specific data are required for each grade and container-closure system.

Powders, granules, and premix formulations for veterinary feed use are produced by stepwise dilution of the API onto carriers such as ground corn, rice hulls, or lactose. Mixing is performed in ribbon or paddle mixers; mixer speed, fill level, and mixing time are validated by thief sampling and HPLC assay. Homogeneity acceptance for medicated premix is often set at pooled RSD ≤5.0% for active concentration; lower RSD limits may apply when the final feed inclusion rate is low. Segregation in bulk bins and screw conveyors is controlled by matching API particle size to carrier particle size and by avoiding excessive fines generation. Granules may be prepared by wet massing, extrusion-spheronization, or fluid-bed granulation using binders that do not contain primary amine-reactive aldehydes.

Oral solutions and soluble powders for drinking-water administration require a soluble salt, pH adjustment, or co-solvent. Sulfanilamide base is sparingly soluble in water, so oral solutions frequently use sodium sulfanilamide or buffered vehicles; soluble powder formulations may contain buffering agents to maintain dissolution in hard water. Hard water ions and acidic metal salts can reduce clarity; water quality testing for hardness and iron content is recommended before field use. Protection from light in final containers reduces photochemical discoloration. In all nonsterile powder and solution lines, cleaning validation must prevent cross-contamination into non-sulfonamide feed lines because sulfonamide residues in food-producing animals are regulated in edible tissues and milk.

When Sulfanilamide Is Compared with Substituted and Potentiated Sulfonamides

Sulfanilamide differs from later sulfonamide APIs chiefly in molecular weight, potency, solubility, and metabolism. It lacks the pyrimidinyl, methoxy, or methyl substituents that increase antibacterial potency and extend elimination half-life. Consequently, veterinary formulations containing sulfanilamide often use higher dose rates and shorter dosing intervals than formulations containing sulfadiazine or sulfadimethoxine. The unsubstituted structure also produces a polar molecule with lower lipid solubility; this can reduce tissue penetration but favors renal excretion. The mechanism of action remains competitive inhibition of dihydropteroate synthase, so cross-resistance with other sulfonamides is expected. Minimum inhibitory concentrations are isolate-specific, and susceptibility testing is required for clinical efficacy claims.

Differentiating physical and chemical properties are shown in Table 2. Potentiated combinations require simultaneous assay of two actives and ratio uniformity, while single sulfanilamide products require sulfonamide-related impurity tracking. The primary aromatic amine in sulfanilamide is analytically active in diazotization titration; it also imposes constraints against aldehyde-containing excipients, nitrite salts, and strong oxidizing agents. Sulfanilamide should not be combined with local anesthetics containing para-aminobenzoic acid derivatives, because para-aminobenzoic acid antagonism can reduce antibacterial activity.

Selection of sulfanilamide instead of a substituted sulfonamide should be based on approved target species, residue depletion data, and local regulatory status. Sulfanilamide has an extensive historical toxicology database, but acquired resistance is documented across veterinary isolates. Regulatory acceptance and withdrawal periods for food-producing species are jurisdiction-specific; in some markets, use in lactating dairy cattle is restricted or prohibited due to milk residue concerns.

Storage Conditions and Incompatibilities Define the Processing Envelope

The crystalline veterinary grade is stored in well-closed containers under light protection at controlled room temperature, typically 20–25 °C with excursions defined by the manufacturer. High relative humidity above 60% can increase particle agglomeration and reduce flow; pre-drying may be required before dry processing. Sulfanilamide is incompatible with strong oxidizing agents, nitrite salts, and aldehyde-functional excipients under moist conditions. Contact with copper or iron can promote discoloration in solution; stainless steel or glass-lined equipment is used for liquid manufacturing. Containers should be resealed promptly after use to limit exposure to oxygen and moisture.

For injectable and oral solution manufacturing, aqueous stock solutions are prepared fresh or held under controlled temperature and light conditions after chemical and microbiological stability data are generated. Prolonged storage of alkaline sulfanilamide solutions can increase hydrolysis or oxidative degradation, so pH and color are monitored as in-process controls. Microbial limits for nonsterile dosage forms should comply with USP <61> and USP <62>; objectionable organisms such as Escherichia coli and Salmonella are absent by site-specific test methods. Industrial hygiene controls include dust extraction and local exhaust ventilation when handling micronized powder, because sulfonamide hypersensitivity reactions are documented in exposed workers.